Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in the first half of 2024.
Similar Posts
Piper Sandler upgrades Celanese to neutral, cites moderated downside risk
Post Content Post Views: 157
Alabama city weighs change in body-cam release policy after public outcry
Post Content Post Views: 128
Ashish Kacholia’s portfolio hits ₹3,000 crore with multiple multibaggers
Post Content Post Views: 190
Hunter Biden offers to testify publicly in House Republicans’ probe
Post Content Post Views: 131
Cellnex speeds asset sales in drive for investment grade – CEO
Post Content Post Views: 155
Ex-Wells Fargo CEO sues bank for $34 million in withheld pay, stock
Post Content Post Views: 131